Validated using a knockout cell lineRecombinantRabMAb

Recombinant Anti-C1q antibody [4.8] - Low endotoxin, Azide free (ab227072)

Submit a review Submit a question References (6)
Immunohistochemistry (Frozen sections) - Anti-C1q antibody [4.8] - Low endotoxin, Azide free (ab227072)
  • Anti-C1q antibody [4.8] - Low endotoxin, Azide free (ab227072)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [4.8] to C1q - Low endotoxin, Azide free
  • Suitable for: IHC-Fr
  • Knockout validated
  • Reacts with: Mouse

Overview

  • Product name

    Anti-C1q antibody [4.8] - Low endotoxin, Azide free
    See all C1q primary antibodies

  • Description

    Rabbit monoclonal [4.8] to C1q - Low endotoxin, Azide free

  • Host species

    Rabbit

  • Tested applications

    Suitable for: IHC-Frmore details

  • Species reactivity

    Reacts with: Mouse

  • Immunogen

    Full length native protein (purified).

  • Positive control

    • IHC-Fr: Mouse brain tissue (adult) .

  • General notes

    ab227072 is the carrier-free version of ab182451.

    This antibody was developed as part of a collaboration between Abcam and the lab of Ben A. Barres at Stanford University: Alexander H. Stephan et al., A Dramatic Increase of C1q Protein in the CNS during Normal Aging ,The Journal of Neuroscience.

    Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.

    This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

    Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Our Low endotoxin, azide-free formats have low endotoxin level (≤ 1 EU/ml, determined by the LAL assay) and are free from azide, to achieve consistent experimental results in functional assays.

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab227072 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr
Use at an assay dependent concentration.

ab199376 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
Notes
IHC-Fr
Use at an assay dependent concentration.

ab199376 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

Target

  • Function

    C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.

  • Involvement in disease

    Defects in C1QA are a cause of complement component C1q deficiency (C1QD) [MIM:613652]. A rare defect resulting in C1 deficiency and impaired activation of the complement classical pathway. C1 deficiency generally leads to severe immune complex disease with features of systemic lupus erythematosus and glomerulonephritis.

  • Sequence similarities

    Contains 1 C1q domain.
    Contains 1 collagen-like domain.

  • Post-translational
    modifications

    O-linked glycans consist of Glc-Gal disaccharides bound to the oxygen atom of post-translationally added hydroxyl groups.

  • Cellular localization

    Secreted.
  • Information by UniProt

  • Database links

    • Alternative names

      • C1qa antibody
      • C1QA_HUMAN antibody
      • C1QB antibody
      • C1QC antibody
      • Complement C1q subcomponent subunit A antibody
      • Complement C1q subcomponent subunit B antibody
      • Complement C1q subcomponent subunit C antibody
      • Complement component 1 q subcomponent alpha polypeptide antibody
      • Complement component C1q A chain antibody
      • Complement component C1q B chain antibody
      • Complement component C1q C chain antibody
      see all

    Images

    • Immunohistochemistry (Frozen sections) - Anti-C1q antibody [4.8] - Low endotoxin, Azide free (ab227072)
      Immunohistochemistry (Frozen sections) - Anti-C1q antibody [4.8] - Low endotoxin, Azide free (ab227072)This image is kindly provided by Dr. Daniel Wilton from Boston Children’s Hospital.

      Immunohistochemistry (Frozen sections) analysis of 15 µm coronal brain sections from postnatal day 90 C1qA knockout mice and wild-type litter-mates (Botto et al., 1998) labeling C1q with ab227072 at 1/500 dilution. Tissues fixed with 4% paraformaldehyde, and permeabilized using 0.3% triton. Goat anti-Mouse IgG H&L (Alexa Fluor® 594) at 1/500 dilution was used as the secondary antibody (red). Nuclei counterstained with DAPI (teal).

    • Anti-C1q antibody [4.8] - Low endotoxin, Azide free (ab227072)
      Anti-C1q antibody [4.8] - Low endotoxin, Azide free (ab227072)

    Protocols

    To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

    Click here to view the general protocols

    References (6)

    Publishing research using ab227072? Please let us know so that we can cite the reference in this datasheet.

    ab227072 has been referenced in 6 publications.

    • Lall D  et al. C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation. Neuron 109:2275-2291.e8 (2021). PubMed: 34133945
    • Silverman SM  et al. C1q propagates microglial activation and neurodegeneration in the visual axis following retinal ischemia/reperfusion injury. Mol Neurodegener 11:24 (2016). IHC-Fr ; Mouse . PubMed: 27008854
    • Hong S  et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352:712-6 (2016). IHC ; Mouse . PubMed: 27033548
    • Lui H  et al. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell 165:921-35 (2016). ICC/IF ; Mouse . PubMed: 27114033
    • Chung WS  et al. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proc Natl Acad Sci U S A 113:10186-91 (2016). IHC-P ; Mouse . PubMed: 27559087
    • Stephan AH  et al. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci 33:13460-74 (2013). IHC-FoFr ; Mouse . PubMed: 23946404

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab227072.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com